Opendata, web and dolomites

CAR ART SIGNED

Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAR ART project word cloud

Explore the words cloud of the CAR ART project. It provides you a very rough idea of what is the project "CAR ART" about.

action    receptor    lab    pharmacologie    transfer    graft    child    cd4foxp3    therapy    sufficient    few    markedly    et    clinic    successfully    outgoing    risk    recipient    strategies    global    alloimmune    return    induction    data    enhanced    specificity    survival    france    drugs    car    organ    tregs    limitation    levings    clinically    vivo    regulatory    hindered    valbonne    cellulaire    expanded    experimental    cellular    indefinite    generate    family    potency    relies    potent    infections    performed    group    mol    alloantigens    immunologists    allograft    destructive    supporting    transplant    adoptive    translation    preclinical    antigen    ambition    pr    team    de    glaichenhaus    toward    transplantation    immune    eacute    clinical    vancouver    ex    trial    grail    prevention    models    kidney    institut    life    tenured    fellowship    ing    applicable    indicated    rejection    position    culaire    alloantigen    humoral    treg    chimeric    lack    terminal    limited    treatment    morbidity    human    cancers    donor    overcome    immunosuppressive    redirect    researcher    canada    tolerance    cells   

Project "CAR ART" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 171˙349 €
 EC max contribution 171˙349 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 171˙349.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4FOXP3 regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAR ART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAR ART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

GW (2019)

Analysing the heavy element factories of the Universe : photometric and spectroscopic sample study of kilonovae

Read More